ClinicalTrials.gg
CompletedNCT01592695Updated Aug 2, 2019Results posted

Tailored Tobacco Quitline for Rural Veterans

A Phase 2 interventional study of Nicotine replacement therapy - transdermal nicotine patch and Tailored behavioral intervention in Cigarette Smoking, sponsored by Iowa City Veterans Affairs Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-02.

Sponsored by Iowa City Veterans Affairs Medical Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 371 studies in Cigarette Smoking with a site in United States — 68 open to participants now, 75 under way, 3 of them phase 3. Cigarette Smoking · United States.

Enrollment
217th of 340
63 · median 96
Started
2012
with 14 others
Phase 2
48 of 371
8 open now
Registered
71st of 371
by date

Among the 371 studies in Cigarette Smoking with a site in United States, this one is the 217th largest by enrollment of the 340 interventional ones that give a count, is one of 15 that started in 2012, is one of 48 in phase 2, and was the 71st registered.

Cigarette Smoking

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

Browse Cigarette Smoking studies →

Open to participants now

68 of the 371 studies in Cigarette Smoking with a site in United States are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 371 studies in Cigarette Smoking with a site in United States, or all of them as a file.
02

Study summary

The proposed work is designed to help increase access to tobacco cessation services among rural veterans and to develop more effective treatment services that better address comorbid issues commonly experienced by rural smokers. The objectives are:

  1. Study the feasibility of an individually-tailored telephone intervention for rural smokers.
  2. Examine the impact of the intervention on tobacco use outcomes.
  3. Evaluate the effect of the intervention on issues commonly experienced by rural smokers including depressive symptoms, alcohol use, and weight gain.
Read the detailed description

Tobacco use remains the leading preventable cause of morbidity and mortality in our society. Results from epidemiologic studies indicate that tobacco use is especially elevated among those living in rural areas. Although interventions exist that are both effective and cost-effective, few rural smokers utilize them during any given quit attempt. A lack of local treatment resources, the travel distance required to obtain treatment, and a reduced tendency to visit primary care on a regular basis all appear to contribute to the lower levels of treatment for nicotine dependence in rural smokers.

Smokers frequently experience conditions and concerns that adversely impact their ability to quit smoking. Depression and risky alcohol use, both of which are prevalent among smokers, reduce the likelihood of successfully quitting smoking. Concern about gaining weight, a common consequence of quitting smoking, is also frequently cited by smokers as an important barrier to quitting. Therefore, in order to be most effective, tobacco cessation interventions will need to address these important issues. Presently, treatment for nicotine dependence, risky alcohol use, depression, and weight management is typically delivered separately and without optimal integration among providers, an approach which only serves to fragment care and increase the number of required visits, further reduce rural smokers' access to care.

In an effort to address these barriers, the current study will evaluate a telephone intervention for tobacco use that also addresses issues related to risky alcohol use, depressed mood, and postcessation weight gain based on each individual smoker's needs. Results will provide valuable information regarding the potential to more widely implement an individually-tailored telephone intervention for rural smokers.

03

Conditions studied

  • Cigarette Smoking

Keywords

  • Nicotine dependence
  • Smoking cessation
  • Telehealth
  • Alcohol use
  • Depression
  • Body weight
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being a veteran
  • 18 + years of age
  • Smoke cigarettes on at least a daily basis
  • Receive primary care from the Iowa City VAMC or Coralville Clinic
  • Live in a non-metropolitan area (based on RUCA codes)
  • Be willing to make a quit attempt in the next 30 days
  • Be capable of providing
  • Have access to a telephone (land line or cell phone)
  • Have a stable residence

Exclusion criteria

Exclusion Criteria:

  • Planning to move within the next 12 months
  • Presence of a terminal illness
  • Pregnancy
  • Unstable psychiatric disorder (e.g., acute psychosis)
  • Currently pregnant
  • Incarcerated
  • Institutionalized
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Tailored Intervention Group

    Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.

    Drug: Nicotine replacement therapy - transdermal nicotine patch · Behavioral: Tailored behavioral intervention · Drug: Nicotine replacement therapy - nicotine gum · Drug: Nicotine replacement therapy - nicotine lozenge · Drug: Bupropion Sustained Release · Drug: Varenicline · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge · Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion · Behavioral: Alcohol use risk reduction · Behavioral: Behavioral activation for the treatment of depression · Behavioral: Behavioral management of post-cessation weight gain

  • Active comparator
    Enhanced Standard of Care Group

    Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.

    Drug: Nicotine replacement therapy - transdermal nicotine patch · Behavioral: Tobacco quit line referral · Drug: Nicotine replacement therapy - nicotine gum · Drug: Nicotine replacement therapy - nicotine lozenge · Drug: Bupropion Sustained Release · Drug: Varenicline · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum · Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge · Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion

Interventions

  • DrugNicotine replacement therapy - transdermal nicotine patch

    Medication selection will be determined based on individual participant preferences, medical history, and contraindications.

  • BehavioralTailored behavioral intervention

    Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.

  • BehavioralTobacco quit line referral

    Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.

  • DrugNicotine replacement therapy - nicotine gum

    Medication selection will be determined based on individual participant preferences, medical history, and contraindications

  • DrugNicotine replacement therapy - nicotine lozenge

    Medication selection will be determined based on individual participant preferences, medical history, and contraindications

  • DrugBupropion Hydrochloride Controlled-releaseStudies of Bupropion Hydrochloride Controlled-releaseBupropion Hydrochloride Controlled-release pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Medication selection will be determined based on individual participant preferences, medical history, and contraindications

    Also known as: Zyban

  • Medication selection will be determined based on individual participant preferences, medical history, and contraindications

    Also known as: Chantix

  • DrugCombination pharmacotherapy - transdermal nicotine patch + nicotine gum

    Medication selection will be determined based on individual participant preferences, medical history, and contraindications

  • DrugCombination pharmacotherapy - transdermal nicotine patch + nicotine lozenge

    Medication selection will be determined based on individual participant preferences, medical history, and contraindications

  • DrugCombination pharmacotherapy - transdermal nicotine patch + bupropion

    Medication selection will be determined based on individual participant preferences, medical history, and contraindications

  • BehavioralAlcohol use risk reduction

    Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.

    Also known as: Risky alcohol use, Harm reduction

  • BehavioralBehavioral activation for the treatment of depression

    Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.

    Also known as: Depression

  • BehavioralBehavioral management of post-cessation weight gain

    Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.

    Also known as: Weight management

06

What researchers measure

Primary outcomes

  1. Treatment Satisfaction

    Participants' impressions of and satisfaction with the intervention will be assessed by interview at the end of treatment.

    Time frame: End of treatment (seven weeks after baseline)

Secondary outcomes

  1. Number of Participants Abstinent From Tobacco Use

    At the six-month follow-up contact, participants will be questioned regarding self-reported tobacco use over the past seven days (point prevalence abstinence).

    Time frame: Six-month follow-up

  2. Alcohol Use

    Alcohol use during the previous seven days will be assessed among those receiving the risky alcohol use treatment module and those in the quitline referral condition who would have been eligible for the intervention if assigned to the tailored treatment group.

    Time frame: Six-month follow-up

  3. Depressive Symptoms

    Depressive symptoms as measured using the Patient Health Questionnaire 9 (PHQ-9). Possible scores range from 0 to 27, with higher scores indicating greater levels of depressive symptoms.

    Time frame: Six-month follow-up

  4. Body Weight

    Self-reported body weight.

    Time frame: Six-month follow-up

  5. Enrollment Rate

    The number of participants enrolled will be tracked as a measure of the feasibility of the intervention approached for the entire six-month recruitment period.

    Time frame: 6 months after study initiation

  6. Retention

    The number of participants who remain in the study throughout the seven-week treatment period will be computed as an indicator of the feasibility of the treatment approach.

    Time frame: End of treatment (seven weeks after baseline)

  7. Treatment Attendance

    The number of treatment calls completed (out of six total) will be calculated for all participants in the Tailored Intervention group as an indicator of the feasibility of the treatment approach.

    Time frame: End of treatment (seven weeks after baseline)

07

Results

Posted Jul 19, 2017

Participant flow

Participant flow — Overall Study
MilestoneTailored Intervention GroupEnhanced Standard of Care Group
Started3132
Completed2328
Not completed84
Withdrew: Lost to follow-up84

Outcome measures

PrimaryTreatment Satisfaction

Participants' impressions of and satisfaction with the intervention will be assessed by interview at the end of treatment.

Time frame:
End of treatment (seven weeks after baseline)
Reported as:
Count of participants · Participants
Treatment Satisfaction
ParticipantsTailored Intervention GroupEnhanced Standard of Care Group
Found treatment very or extremely useful176
Found medication to be very or extremely useful167
Found treatment to be very or extremely convenient169
Found treatment to be very or extremely difficult55
Liked that treatment was delivered by phone2110
SecondaryNumber of Participants Abstinent From Tobacco Use

At the six-month follow-up contact, participants will be questioned regarding self-reported tobacco use over the past seven days (point prevalence abstinence).

Time frame:
Six-month follow-up
Reported as:
Count of participants · Participants
Number of Participants Abstinent From Tobacco Use
ParticipantsTailored Intervention GroupEnhanced Standard of Care Group
Number of Participants Abstinent From Tobacco Use99
SecondaryAlcohol Use

Alcohol use during the previous seven days will be assessed among those receiving the risky alcohol use treatment module and those in the quitline referral condition who would have been eligible for the intervention if assigned to the tailored treatment group.

Time frame:
Six-month follow-up
Reported as:
Mean · Drinks consumed per day
Alcohol Use
Drinks consumed per dayTailored Intervention GroupEnhanced Standard of Care Group
Alcohol Use9.5 ± 0.72.8 ± 3.2
SecondaryDepressive Symptoms

Depressive symptoms as measured using the Patient Health Questionnaire 9 (PHQ-9). Possible scores range from 0 to 27, with higher scores indicating greater levels of depressive symptoms.

Time frame:
Six-month follow-up
Reported as:
Mean · units on a scale
Depressive Symptoms
units on a scaleTailored Intervention GroupEnhanced Standard of Care Group
Depressive Symptoms7.0 ± 5.43.9 ± 2.7
SecondaryBody Weight

Self-reported body weight.

Time frame:
Six-month follow-up
Reported as:
Mean · Pounds
Body Weight
PoundsTailored Intervention GroupEnhanced Standard of Care Group
Body Weight214.0 ± 38.1228.2 ± 45.5
SecondaryEnrollment Rate

The number of participants enrolled will be tracked as a measure of the feasibility of the intervention approached for the entire six-month recruitment period.

Time frame:
6 months after study initiation
Reported as:
Count of participants · Participants
Enrollment Rate
ParticipantsTailored Intervention GroupEnhanced Standard of Care Group
Enrollment Rate3132
SecondaryRetention

The number of participants who remain in the study throughout the seven-week treatment period will be computed as an indicator of the feasibility of the treatment approach.

Time frame:
End of treatment (seven weeks after baseline)
Reported as:
Count of participants · Participants
Retention
ParticipantsTailored Intervention Group
Retention16
SecondaryTreatment Attendance

The number of treatment calls completed (out of six total) will be calculated for all participants in the Tailored Intervention group as an indicator of the feasibility of the treatment approach.

Time frame:
End of treatment (seven weeks after baseline)
Reported as:
Mean · Calls
Treatment Attendance
CallsTailored Intervention Group
Treatment Attendance4.0 (0 to 6)

Adverse events

Collected over Six months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tailored Intervention Group0/31 (0%)0/31 (0%)0/31 (0%)
Enhanced Standard of Care Group0/32 (0%)0/32 (0%)0/32 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
<=18 years000
Between 18 and 65 years262955
>=65 years538
Age, Continuous
Age, Continuous(years)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
Mean55.1 ± 11.558.5 ± 8.856.8 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
Female358
Male282755
Region of Enrollment
Region of Enrollment(Participants)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
United States313263
Nicotine dependence
Nicotine dependence(units on a scale)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
Mean5.6 ± 2.35.7 ± 2.15.7 ± 2.2
Cigarettes smoked per day
Cigarettes smoked per day(cigarettes/day)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
Mean22.3 ± 10.327.2 ± 25.724.7 ± 19.4
Prior quit attempts lasting at least 24 hours
Prior quit attempts lasting at least 24 hours(quit attempts)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
Mean6.6 ± 8.19.4 ± 19.68.0 ± 15.0
Readiness to quit smoking
Readiness to quit smoking(units on a scale)Tailored Intervention GroupEnhanced Standard of Care GroupTotal
Mean6.8 ± 1.16.5 ± 1.36.6 ± 1.2

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Iowa City VA Health Care System
    Iowa City, Iowa 52246, United States
09

References and documents

Publications

  • Vander Weg MW, Cozad AJ, Howren MB, Cretzmeyer M, Scherubel M, Turvey C, Grant KM, Abrams TE, Katz DA. An individually-tailored smoking cessation intervention for rural Veterans: a pilot randomized trial. BMC Public Health. 2016 Aug 17;16(1):811. doi: 10.1186/s12889-016-3493-z. PubMed 27535024 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2012
First posted
May 7, 2012
Start
Jun 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Jul 19, 2017
Last update
Aug 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01592695
Lead sponsor
Iowa City Veterans Affairs Medical Center
Responsible party
Mark Vander Weg (Research Specialist, Iowa City Veterans Affairs Medical Center) — Principal investigator
First posted
May 7, 2012
Start date
Jun 2012
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Jul 19, 2017
Last update
Aug 2, 2019

Study contacts

Mark VanderWeg, PhD
principal investigator · VRHRC-CR

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion